Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival

Sandrine Niyongere, MD, Yamini Kathari, MD, Zeba Singh, MD, Emily J. Vannorsdall, MD, Ashkan Emadi, MD, PhD, Vu Doung, MD, M.S., Maria R. Baer, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142747

Published: 2020

Journal Articles

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Ashkan Emadi, MD, PhD, Vu H. Duong, MD, Sandrine Niyongere, MD, Wendy Walinski, Meriem Said, Stephanie Halliwell, Kemji Eke, Kristopher Attwood, PhD, Maria R. Baer, MD, Eunice S. Wang, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141736

Published: 2020

Journal Articles

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Gabriela Sanchez-Petitto, MD, Olga Goloubeva, PhD MSc, James Childress, MD, Tahreem Iqbal, MD, Jack Masur, MD, Max An, BS, Safwan Muhammad, MD, Justin Lawson, PharmD BCOP, Jasmin Sahbaz, MD, Brian Barr, MD, Vu H. Duong, MD, Jennie Y. Law, MD, Ashkan Emadi, MD, PhD, Maria R. Baer, MD, Sandrine Niyongere, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138534

Published: 2020

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Eric Padron, MD, Amy E. DeZern, MD, Sandrine Niyongere, MD, Markus Christian Ball, PhD, Maria Balasis, Hanadi Ramadan, BA, Jeffrey E. Lancet, MD, Alan F List, MD, Ruben A Mesa, MD, Gail J. Roboz, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 162.

https://doi.org/10.1182/blood.V130.Suppl_1.162.162

Published: 2017

Journal Articles

Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML)

Sandrine Niyongere, MD, Nolwenn Lucas, Samir Sansil, Christopher L Cubitt, PhD, Maria E. Balasis, Jodi Kroeger, Qing Zhang, MD, John J Ceremsak, Elliot Stieglitz, MD, YuLong Zhao, PhD, Markus Ball, PhD, Rami S. Komrokji, MD, Alan F List, MD, Valeria Santini, MD, Eric Solary, Eric Padron, MD

Blood (2016) 128 (22): 109.

https://doi.org/10.1182/blood.V128.22.109.109

Published: 2016

NARROW

Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only